Highlights Gufic Biosciences Limited

Equities

GUFICBIO

INE742B01025

Delayed Bombay S.E. Other stock markets 02:24:43 28/05/2024 pm IST			5-day change	1st Jan Change
312.3 ^INR	-2.15%		-9.50%	-1.01%

25/04	Gufic Biosciences Limited Approves Reconstitution of Various Committees	CI
04/04	Gufic Biosciences Forms New Wholly-Owned Arm in Dubai	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gufic Biosciences Forms New Wholly-Owned Arm in Dubai	04/04	MT
Gufic Biosciences Limited Incorporates Wholly Owned Subsidiary Company in Dubai	03/04	CI
Gufic Biosciences Secures Patent in India	15/03	MT
Gufic Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Gufic Biosciences Gets New Patent in India	31/01	MT
Gufic Biosciences Forms New Pharmaceutical Subsidiary	20/11	MT
Gufic Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection	09/11	CI
Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2023	30/23/30	CI
Gufic Biosciences Limited Approves Incorporation of Wholly Owned Subsidiary in Dubai, UAE	27/23/27	CI
Ex-dividend day for final dividend	21/23/21	FA
Gufic Biosciences Granted Patent for its Invention	15/23/15	MT
Gufic Biosciences Gets Nod from Australian, Brazilian Regulators for Parecoxib Sodium Lyophilized Powder	12/23/12	MT
Gufic Biosciences Limited Receives Approval of TGA, Australia and the National Health Surveillance Agency, Brazil for Parecoxib 40Mg Injection	11/23/11	CI
Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023	06/23/06	CI
Motilal Oswal Financial to Acquire 3% Stake in Gufic Biosciences for INR1 Billion	01/23/01	MT
Gufic Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Gufic Biosciences Limited Receives Approval from NMPA, China for Prilocaine API	16/23/16	CI
Gufic Biosciences Limited Receives Approval from the Drug Controller General of India for Both Dalbavancin Api and Formulation	30/23/30	CI
Gufic Biosciences Limited Recommends Dividend for the Financial Year Ended March 31, 2023	29/23/29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gufic Biosciences Limited

Equities

GUFICBIO

INE742B01025

Highlights

Filters